| Members |
targetComponentId |
| Dried factor IX fraction heated 600iu powder and solvent for injection solution vial (product) |
Product containing only coagulation factor IX in parenteral dose form (medicinal product form) |
| Dried factor IX fraction heated 600iu powder for conventional release solution for injection solution vial (product) |
Product containing only coagulation factor IX in parenteral dose form (medicinal product form) |
| Drimaren brilliant yellow |
Textile colours and finishes patch test substance |
| Drostanolone propionate allergy |
Allergy to drostanolone (finding) |
| Drotrecogin alfa (activated) 5mg powder for infusion solution vial (product) |
Drotrecogin alfa 5 mg powder for solution for injection vial |
| Drotrecogin alfa 20mg powder for infusion solution vial (product) |
Product containing precisely drotrecogin alfa 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Drug |
produit pharmaceutique ou biologique |
| Drug aerosol, 0,01% |
médicament en aérosol |
| Drug aerosol, 0,04% (product) |
médicament en aérosol |
| Drug aerosol, 0,5% (product) |
médicament en aérosol |
| Drug cream, 0,01% (product) |
Cream |
| Drug cream, 0,02% (product) |
Cream |
| Drug cream, 0,025% (product) |
Cream |
| Drug cream, 0,05% (product) |
Cream |
| Drug cream, 0,1% (product) |
Cream |
| Drug cream, 0,25% |
Cream |
| Drug cream, 0,5% (product) |
Cream |
| Drug cream, 1% (product) |
Cream |
| Drug cream, 2,5% (product) |
Cream |
| Drug gel, 0,05% (product) |
Gel |
| Drug gel, 0,1% |
Gel |
| Drug gel, 0,25% (product) |
Gel |
| Drug groups primarily affecting the autonomic nervous system (product) |
médicament pour le système nerveux autonome |
| Drug ointment, 0,025% (product) |
Ointment |
| Drug ointment, 0,05% (product) |
Ointment |
| Drug ointment, 0,1% |
Ointment |
| Drug ointment, 0,2% (product) |
Ointment |
| Drug ointment, 0,25% (product) |
Ointment |
| Drug ointment, 1% (product) |
Ointment |
| Drug ointment, 2,5% (product) |
Ointment |
| Drug specific allergen extract (product) |
produit pharmaceutique ou biologique |
| Drug withdrawal seizure |
Seizure co-occurrent and due to drug withdrawal (disorder) |
| Drug, medicament or biological substance |
Drug or medicament (substance) |
| impuissance médicamenteuse |
Erectile dysfunction caused by drug |
| Drug-related disorder |
Disease |
| Drusen |
Hyaline body |
| Duct ectasia |
dilatation |
| Ductal carcinoma in situ - category (morphologic abnormality) |
Non-infiltrating intraductal carcinoma |
| Dukes-Filatow disease (disorder) |
Rubeola scarlatinosa |
| Dundee cardiovascular risk score (assessment scale) |
Dundee Coronary Risk Disk (assessment scale) |
| Duodenitis caused by ingestible alcohol (disorder) |
Duodenitis caused by ethanol (disorder) |
| Duodenoscopy: [diagnostic NOS] or [NEC] |
Duodenoscopy |
| rapport en double |
Duplicate report (record artifact) |
| Dyclonine hydrochloride 1% topical solution (product) |
Product containing precisely dyclonine hydrochloride 10 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
| Dynamite |
Dynamite stick (physical object) |
| Dyphylline + guaifenesin 100mg/100mg elixir (product) |
Dyphylline 6.67 mg/mL and guaifenesin 6.67 mg/mL oral solution |
| Dyphylline 160mg/15ml elixir (product) |
Dyphylline 10.7 mg/mL oral solution |
| Dyskinesia of esophagus |
Diffuse spasm of esophagus |
| Dyssegmental dysplasia with glaucoma syndrome (disorder) |
Rolland-Debuqois syndrome |
| Dyssocial behavior of child or adolescent |
Dyssocial behavior of child or adolescent (finding) |
| Dysthyroid ophthalmopathy (disorder) |
Exophthalmos due to thyroid eye disease (disorder) |
| rapport envoyé par courriel |
rapport par courriel (élément du dossier) |
| ECG equivocal |
ECG equivocal |
| ECG: left ventricular strain |
Electrocardiographic left ventricular strain (finding) |
| Ear flap |
Flap (substance) |
| Ear sign or symptom (finding) |
constatation à propos de l'oreille et de l'audition |
| Early onset pauciarticular chronic arthritis |
Juvenile idiopathic arthritis, oligoarthritis (disorder) |
| Ebola virus (organism) |
virus Ebola |
| Ebola virus Ivory Coast subtype (organism) |
Ivory Coast ebolavirus (organism) |
| Ebola virus Reston biotype (organism) |
Reston ebolavirus (organism) |
| Ebola virus Sudan biotype |
Sudan ebolavirus (organism) |
| Ebola virus Zaire biotype |
Zaire virus (organism) |
| Ebola virus disease |
Viral hemorrhagic fever, Ebola |
| Echinococcus granulosus infection of other site (disorder) |
Echinococcus granulosus infection |
| Echinococcus multilocularis infection of other site |
Echinococcus multilocularis infection |
| Echinocyte |
Burr cell (cell) |
| Echothiophate iodide 0.03% eye drops |
Echothiophate iodide 300 microgram/mL eye solution |
| Echothiophate iodide 0.06% eye drops |
Echothiophate iodide 600 microgram/mL eye solution |
| Echothiophate iodide 0.125% solution (product) |
Echothiophate (as echothiophate iodide) 1.25 mg/mL eye solution |
| Echothiophate iodide 0.25% eye drops |
Echothiophate iodide 2.5 mg/mL eye solution |
| Econazole nitrate 150mg/1% pessaries+cream (product) |
Econazole only product |
| Ecothiopate iodide 0.125% eye drops (product) |
Echothiophate iodide 1.25 mg/mL eye solution |
| Ectopic hormone secretion, NEC |
Ectopic production of endocrine substance |
| Eczema of leg |
Eczema of lower limb |
| Edetate disodium 150mg/mL injection solution ampule (product) |
Edetate disodium 150 mg/mL solution for injection |
| Educational status |
Educational achievement |
| Educational therapy |
Educational therapy |
| Edwardsiella anguillimortifera |
Edwardsiella tarda |
| Eel - dietary |
Eel (substance) |
| Eflornithine hydrochloride 13.9% cream (product) |
Eflornithine (as eflornithine hydrochloride) 139 mg/mL cutaneous cream |
| Eflornithine hydrochloride 139mg/g cream (product) |
Eflornithine (as eflornithine hydrochloride) 139 mg/mL cutaneous cream |
| EgAN 1824-61 virus |
EgAN 1825-61 virus (organism) |
| Egyptian goose |
Alopochen aegyptiacus |
| Ehlers-Danlos syndrome, dominant type 4 |
Ehlers-Danlos syndrome, type 4 |
| Ehlers-Danlos syndrome, recessive type 4 |
Ehlers-Danlos syndrome, type 4 |
| Ehrlichia equi |
Anaplasma phagocytophilum (organism) |
| Ehrlichia phagocytophila (organism) |
Anaplasma phagocytophilum (organism) |
| Ehrlichia platys |
Anaplasma platys |
| Ehrlichia risticii |
Neorickettsia risticii (organism) |
| Ehrlichia sennetsu |
Neorickettsia sennetsu (organism) |
| Ejaculatio tarda |
Late ejaculation |
| Ejaculation (observable entity) |
Ejaculation (observable entity) |
| Elapid snake |
Family Elapidae |
| Electrical fitter (general) |
Electrical fitter |
| Electrolyte and fluid disorder, NEC |
déséquilibre hydroelectrolytique |
| Electrolyte anion agent (substance) |
Electrolyte anion (substance) |
| Electromyogram |
électromyographie |
| Electron |
Electron |
| Elevated |
High |
| Embden-Meyerhof pathway (substance) |
Embden-Meyerhof pathway, function (observable entity) |
| Emblema guttata |
Stagonopleura guttata (organism) |
FHIR